Clinical Trial Update: Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial at the University of Alabama at Birmingham is studying whether pneumococcal conjugate vaccines induce cross-protective antibodies again…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pneumococcal conjugate vaccine (pneumococcal conjugate vaccine)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Vaccine, Pneumococcal Disease | Phase 4 | Status: NOT_YET_RECRUITING